Dual antibody therapy reduces SARS-CoV-2 viral load by modest –0.57 log at day 11

Latest update on HIV and COVID-19 from BHIVA and EACS (January 2021)

Monoclonal antibody bamlanivimab is not effective in advanced COVID-19: lack of early signal stops study early

Novavax phase 3 vaccine study launched in the UK, South Africa, US, Mexico and Puerto Rico

Pfizer COVID-19 vaccine might still overcome UK and SA variants

Azithromycin monotherapy shows no benefit for COVID-19: RECOVERY study reports 1493 further deaths

WHO strongly recommended against using hydroxychloroquine or lopinavir/r at any stage of COVID-19

Very low-level viral load viraemia might continue after COVID-19

Updated US guidelines for treating COVID-19 (December 2020)

Webcasts of two-day US Workshop on long COVID now online

US update guidelines on access to COVID vaccines

NICE issue UK guidelines on long COVID

Recent studies on HIV and COVID-19 coinfection

Early safety and immune responses in older people using the Oxford vaccine: overall results complicated by dosing error

Interim results report 94% efficacy with Moderna/NIH mRNA vaccine: FDA hearing on 17 December

HIV risk from some COVID-19 vaccines might be unlikely due to rarity of vector viruses involved

Hydroxychloroquine fails to prevent COVID-19 or SARS-CoV-2 transmission when used as PEP

Hydroxychloroquine has no benefit on symptoms at 14 days

WHO SOLIDARITY study published in NEJM

International COVID-19 study launches in Africa but with drugs that have little chance of working (ANTICOV)

Serious complications commonly reported three months after recovery from COVID-19

Adverse pregnancy outcomes among Spanish women hospitalised with COVID-19

COVID-19 antibody testing for HIV positive people in the UK: HIV organisations reverse previous exclusion

HIV positive people at higher risk of worse outcomes from COVID-19 in UK study

Remdesivir given full approval by the US FDA, but on limited data

DSMB stops REGN-COV2 (casirivimab/imdevimab) monoclonal antibody study in people with high-flow oxygen or ventilation: implications for UK RECOVERY study

Monoclonal antibody stopped in ACTIV-3 study: bamlanivimab shows lack of benefit in people hospitalised with COVID-19

Early results report 90% efficacy with from Pfizer/BioNTech COVID vaccine

Convalescent plasma: randomised controlled study finds no benefit in moderate stage COVID-19

No survival benefit from remdesivir, hydroxychloroquine, lopinavir/r or interferon-β1a in moderate and severe COVID-19: interim results from the WHO SOLIDARITY study

COVID-19: pathogenesis and treatment 

US study of HIV positive people with COVID-19 reports worse outcomes with comorbidities and having a CD4 <200

Outcomes from COVID-19 in French cohort of 54 HIV positive people on ART

Tocilizumab fails to meet clinical endpoints in randomised COVACTA study: other studies continue

COVID-19 reinfection can occur after varying times and with more severe disease

Transmission from children to family members in US childcare setting

BHIVA update guidance for HIV care during second wave of COVID-19

COVID-19 deaths in children and people <21 years old in the US

IDSA guidelines on serologic testing for SARS-CoV-2

Long COVID: Mild infection and sustained long-term complications

Review paper highlights substandard COVID-19 research in both peer-review journals and pre-review websites

Oxford COVID vaccine enrolling HIV positive people at two London sites

COVID-19 outcomes in HIV positive people in two large US cohorts

HIV associated with worse outcomes from COVID-19 in UK ISARIC and OpenSAFELY databases

European and UK doctors review latest studies on HIV and COVID-19 coinfection

Tocilizumab associated with better outcomes from COVID-19 in US study

Famotidine associated with better outcomes from COVID-19

INSIGHT network to study monoclonal antibodies for COVID-19 including LY-CoV555

US activists ensure people living with HIV can enrol in COVID-19 vaccine studies

HIV organisations oppose active-challenge COVID-19 vaccine studies

AVAC webinar with Barney Graham: COVID-19 vaccine targets, timelines, efficacy and ethical issues

Equitable access to vaccines against COVID-19

Conference opening and making sense of the science

HepC drugs for COVID-19: sofosbuvir/daclatasvir show faster recovery and reduced mortality

Predictors of response to remdesivir in GS-5773 COVID-19 study

Pneumocystis Jirovecii Pneumonia (PJP) mistaken for COVID-19 in late stage undiagnosed: urgency of including HIV testing on admission

NYC cohort reports similar outcomes from COVID-19 in HIV positive vs HIV negative adults

Spanish study reports associations between COVID-19 and HIV treatment including NRTIs

UK study reports inhaled interferon-Beta reduces time to recovery from COVID-19

Review of COVID-19 in people with immune suppression

EMA grants conditional approval for remdesivir in the EU to treat COVID-19

Drug price announced for remdesivir – as US buys up world stock

RECOVERY study reports that lopinavir/r fails to show benefit against COVID-19

Hydroxychloroquine and lopinavir/r arms stopped in the WHO SOLIDARITY study

Individualising management of COVID-19 based on real-time inflammatory responses

Post navigation